Drug intelligence / Profile preview

ABP1011T

Development stage: Phase 2
Lead developer: Shanghai AB PharmaTech
Modality: Small Molecules
Administration: Oral

Overview

ABP1011T is a pharmaceutical drug currently in clinical development for the treatment of advanced malignant solid tumors. It is administered as tablets and is being evaluated in single-arm, open-label Phase 1/2 clinical trials to assess its safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy.

Beyond the preview

Go deeper on ABP1011T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABP1011T.

Explore the full profile